Biotech in a blink

Nature Biotechnology

Volumn 28, Issue 4, 2010, Pages 311-314

  Garber, Ken ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AGENTS ACTING ON THE EYE; ANGIOSTATIN; ARC 1905; BEVACIZUMAB; BEVASIRANIB; E 10030; ECULIZUMAB; ENDOSTATIN; NT 503; PAZOPANIB; PEGAPTANIB; PF 04523655; POT 4; RANIBIZUMAB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG COST; DRUG MECHANISM; EMBRYONIC STEM CELL; HUMAN; NOTE; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; GENE SILENCING; GENE THERAPY; HUMANS; RETINAL NEOVASCULARIZATION;

EID: 77950662306     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0410-311     Document Type: Note

References (7)

1. Brown, D.M. et al. N. Engl. J. Med. 355, 1432-1444 (2006).
2. Jo, N. et al. Am. J. Pathol. 168, 2036-2053 (2006).
3. Maguire, A.M. et al. Lancet 374, 1597-1605 (2009).
4. Nishijima, K. et al. Am. J. Pathol. 171, 53-67 (2007).
5. Lu, B. et al. Stem Cells 27, 2126-2135 (2009).
6. Hu, B.Y. et al. Proc. Natl. Acad. Sci. USA 107, 4335-4340 (2010).
7. Sengupta, N. et al. Mol. Ther. 17, 1594-1604 (2009).